Semaglutide in 2026 Q2: what changed

Between April and June 2026, semaglutide had a good quarter inside the licensed market and a bad one outside it. European regulators cleared an oral tablet, the UK licensed the same tablet three weeks later, and a small trial answered a question that had been sitting open since bariatric surgery patients started asking about GLP-1 drugs. Over the same weeks the FDA proposed to shut off the bulk-substance route that compounders use to supply the molecule, and posted warning letters to three more sellers.

The FDA moved against compounded supply

On 30 April 2026 the agency announced it was proposing to keep semaglutide, tirzepatide and liraglutide off the 503B bulk drug substances list, on a finding that there is no clinical need for outsourcing facilities to compound them from bulk when approved products exist^[1]. The notice ran in the Federal Register the next day under docket FDA-2018-N-3240, with comments invited through 29 June. FDA Commissioner Marty Makary set out the reasoning in one sentence.

When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.

If it is finalised, 503B outsourcing facilities lose the legal basis to compound semaglutide from bulk except during a declared shortage. That is the supply line that carried a lot of American patients through the 2023 to 2025 shortage at a fraction of the branded price. In late June the FDA gave the argument another month, extending the comment deadline to 30 July after requesters said the original 60 days did not allow enough time to work through the clinical, public health and legal questions involved^[2]. No final determination had landed when the quarter closed.

Europe cleared a semaglutide tablet

On 22 May 2026 the EMA published the outcome of the CHMP meeting held 18 to 21 May. The committee "recommended an extension to the marketing authorisation for Wegovy (semaglutide) for weight management to add a daily oral tablet as alternative formulation to weekly subcutaneous injections", in four new strengths: 1.5 mg, 4 mg, 9 mg and 25 mg^[3]. The EMA described it as "the first glucagon-like peptide (GLP-1) receptor agonist for weight management developed for oral use".

The recommended indication does not widen who qualifies. Wegovy tablets "can be used, together with diet and physical activity, in adults with obesity, or in those who are overweight and have at least one weight-related comorbidity"^[3]. Same population, same prescription gate, different delivery. Readers who dislike needles now have a licensed route that does not involve ordering a vial from a website.

The UK licensed it three weeks later

The MHRA approved the semaglutide tablet on 11 June 2026 in the same four strengths, for weight loss and weight management in adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition, alongside a reduced-calorie diet and physical activity^[4]. Julian Beach, the MHRA's executive director for healthcare quality and access, added the line that matters for anyone reading this on a vendor site: "As with all GLP-1 receptor agonists, this is a prescription-only medication"^[4]. Country-level detail sits on our semaglutide regulation pages.

A trial answered the post-surgery question

The quarter's most useful clinical paper was also its smallest. BARI-STEP appeared in Nature Medicine on 22 May 2026. It randomised 70 adults who had lost less than 20% of their baseline weight at least a year after metabolic and bariatric surgery to semaglutide 2.4 mg weekly or placebo, both with lifestyle support, over 68 weeks^[5].

Estimated mean weight change from baseline to week 68 was 18.0% down on semaglutide against 0.4% up on placebo, an adjusted difference of 19.18 percentage points. The authors report that semaglutide "results in substantial and clinically significant body weight reduction along with improvement in metabolic parameters and quality of life, compared to placebo", with a safety profile consistent with what is already known and no new concerns^[5]. Seventy people is a small trial and the follow-up stops at 68 weeks, so this is a first answer rather than a settled one. It is still more than the field had in March.

Three more letters to sellers

Enforcement ran through the whole quarter. On 7 April the FDA posted a March letter to Prime Sciences of Scottsdale, whose catalogue listed semaglutide as GLP1-S alongside retatrutide and tirzepatide under a "laboratory research purposes only" disclaimer, while the same site quoted human weight-loss percentages as marketing copy^[6].

On 16 June it posted two letters dated 8 June, both about compounded product rather than research vials. FITISH of Fort Worth and Medica Weight Loss of Aventura each put their own trading name on compounded semaglutide labels without being the compounder, and each told buyers the product was FDA approved^[7]. The agency's correction is worth memorising: "Compounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities"^[8].

What did not change

The prescription requirement held. A tablet is still a prescription medicine in the EU and the UK, and nothing this quarter altered the position in any country covered by our semaglutide regulation pages. The FDA's standing page on unapproved GLP-1 drugs still names semaglutide among substances "illegally sold" under research-use labelling and then shipped to consumers with dosing instructions^[9].

What also did not change is the pricing problem underneath the FDA proposal. Cutting the compounded route without a cheaper licensed option pushes some people toward the same grey market the agency spent the quarter writing letters about. That tension is not resolved, and it is the thing to watch in the second half of 2026. If you are weighing semaglutide against tirzepatide or waiting on retatrutide, that decision belongs with a clinician who can write the prescription and knows your history.